Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Telix Pharmaceuticals's enterprise value is A$5,499 Mil.
Telix Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$53 Mil. Therefore, Telix Pharmaceuticals's EV-to-EBITDA for today is 103.19.
The historical rank and industry rank for Telix Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ASX:TLX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -46.15 Med: -14.73 Max: 482.86
Current: 103.19
During the past 11 years, the highest EV-to-EBITDA of Telix Pharmaceuticals was 482.86. The lowest was -46.15. And the median was -14.73.
ASX:TLX's EV-to-EBITDA is ranked worse than 94.25% of 400
companies
in the Biotechnology industry
Industry Median: 12.15
vs ASX:TLX: 103.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Telix Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Telix Pharmaceuticals's share price for today is A$15.17.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Telix Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.032.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Telix Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TLX vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's EV-to-EBITDA falls into.
Telix Pharmaceuticals's current Enterprise Value is A$5,499 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Telix Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telix Pharmaceuticals (ASX:TLX) has a EV-to-EBITDA of 103.19 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Telix Pharmaceuticals. According to the industry distribution chart, Telix Pharmaceuticals ranks #377 out of 400 companies in the Biotechnology industry, placing it in the top 94.2%.
Is Telix Pharmaceuticals' EV-to-EBITDA too high?
Telix Pharmaceuticals' current EV-to-EBITDA is 103.19. The Biotechnology industry median EV-to-EBITDA is 12.15. Telix Pharmaceuticals' value of 103.19 is 749.3% above this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #377 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #377 out of 400 companies for EV-to-EBITDA. This places Telix Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.15. Telix Pharmaceuticals' value of 103.19 is 749.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.15, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current EV-to-EBITDA of 103.19 is 749.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Telix Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current EV-to-EBITDA is 103.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (ASX:TLX) is currently considered Possible Value Trap. The stock's GF Value™ is A$43.86, compared to a current price of A$15.17 — trading 65.4% below its estimated fair value. The current EV-to-EBITDA is 103.19 and 749.3% above the Biotechnology industry median of 12.15. Telix Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Telix Pharmaceuticals (ASX:TLX), the current EV-to-EBITDA is 103.19 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (ASX:TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of A$15.17 is trading 65.4% below its estimated GF Value™ of A$43.86.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ASX:TLX:
EV-to-EBITDA: 103.19
GF Value™: A$43.86 vs. price of A$15.17 (65.4% below fair value)
Industry Position: 749.3% above the Biotechnology median (#377 of 400)
No single metric tells the full story. See the ASX:TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
69GF Score
Get the complete analysis for ASX:TLX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TLX has been successfully added to your 
